z-logo
open-access-imgOpen Access
Synthesis, characterization and pharmacological evaluation of different 1,3,4-oxadiazole and acetamide derivatives of ethyl nipecotate
Author(s) -
Khadija Nafeesa,
- Aziz-Ur-Rehman,
Muhammad Athar Abbasi,
Sabahat Zahra Siddiqui,
Shahid Rasool,
Syed Adnan Alı Shah
Publication year - 2017
Publication title -
bulletin of faculty of pharmacy, cairo university /bulletin of faculty of pharmacy, cairo university
Language(s) - English
Resource type - Journals
eISSN - 2090-9101
pISSN - 1110-0931
DOI - 10.1016/j.bfopcu.2017.06.001
Subject(s) - chemistry , acetamide , oxadiazole , carbon 13 nmr , sulfanyl , molecule , sulfonyl , antibacterial activity , combinatorial chemistry , stereochemistry , aryl , electrophile , proton nmr , organic chemistry , bacteria , alkyl , biology , genetics , catalysis
A new series of N-substituted derivatives of 2-[(5-{1-[(4-chlorophenyl)sulfonyl]-3-piperidinyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (6a-w) has been designed and synthesized with multifunctional moieties. The synthesized compounds were evaluated for their antibacterial and anti-enzymatic potential supported by % hemolytic activity. The synthesized compound 5-(1-(4-chlorophenylsulfonyl)-3-piperidinyl)-1,3,4-oxadiazole-2-thiol (3) was stirred with synthesized electrophiles as N-aryl/alkyl/aralkyl-2-bromoacetamide (5a-w) in an aprotic solvent under basic conditions to acquire the target molecules, 6a-w. The spectral analytical techniques of IR, EI-MS, 1H NMR and 13C-NMR were utilized for structural elucidation of synthesized molecules. The antibacterial screening against certain bacterial strains of gram-negative and gram-positive bacteria rendered compound 6i as good inhibitor of gram-negative bacterial strains. The enzyme inhibition revealed low potential against lipoxygenase (LOX) enzyme. The hemolytic study provided valuable information about cytotoxic behavior of synthesized molecules. Keywords: 1,3,4-Oxadiazole, Acetamide, Antibacterial activity, Hemolytic activity, Lipoxygenase inhibitio

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here